Sunday 18 October 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
8.11
0.35
−4.14%
Follow BNTC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (33.21%) | (29.58%) | (33.50%) | (53.01%) |
+8 more TTM periods Free account |
|
| (32.28%) | (28.43%) | (32.70%) | (50.76%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.80%) | (22.72%) | (23.60%) | (44.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.36) | (0.40) | (0.40) | (0.54) | |
Free Cash Flow |
(16.62) | (19.82) | (18.45) | (22.35) | |
Capital Expenditures |
(0.10) | (0.03) | (0.03) | — | |
| Other line items | |||||
Cash ROIC |
(4.65%) | (5.38%) | (4.90%) | (11.85%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.36 | 0.48 | 0.42 | 0.53 | |
Depreciation/Fixed assets |
0.33 | 0.47 | 0.47 | 0.46 | |
Capex/Depreciation |
(1.81) | (0.58) | (0.54) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.40) | (0.40) | (0.54) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026